ArticlePPAR research2010
Effects of Endogenous PPAR Agonist Nitro-Oleic Acid on Metabolic Syndrome in Obese Zucker Rats.
Article in PPAR research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 32 citations in OpenAlex.
- Nitro Fatty Acids (NOMolecules (Basel, Switzerland) · 2021Review
- In Silico-Based Design and In Vivo Evaluation of an Anthranilic Acid Derivative as a Multitarget Drug in a Diet-Induced Metabolic Syndrome Model.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Effects of fatty acid nitroalkanes on signal transduction pathways and airway macrophage activation.Innate immunity · 2021Article
- (Pro)renin receptor antagonist PRO20 attenuates nephrectomy-induced nephropathy in rats via inhibition of intrarenal RAS and Wnt/β-catenin signaling.Physiological reports · 2021Article
- Nitro-Fatty Acid Logistics: Formation, Biodistribution, Signaling, and Pharmacology.Trends in endocrinology and metabolism: TEM · 2019Review
- Discovery of bioactive nitrated lipids and nitro-lipid-protein adducts using mass spectrometry-based approaches.Redox biology · 2019Review
- Role of (pro)renin receptor in albumin overload-induced nephropathy in rats.American journal of physiology. Renal physiology · 2018Article
- The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development.International journal of molecular sciences · 2018Review
- Inflammatory signaling and metabolic regulation by nitro-fatty acids.Nitric oxide : biology and chemistry · 2018Review
- Profile of Arachidonic Acid-Derived Inflammatory Markers and Its Modulation by Nitro-Oleic Acid in an Inherited Model of Amyotrophic Lateral Sclerosis.Frontiers in molecular neuroscience · 2018Article
- PPARγ signaling and emerging opportunities for improved therapeutics.Pharmacological research · 2016Review
- Protection of nitro-fatty acid against kidney diseases.American journal of physiology. Renal physiology · 2016Review
- Nitro-fatty acids in cardiovascular regulation and diseases: characteristics and molecular mechanisms.Frontiers in bioscience (Landmark edition) · 2016Review
- Nitrooleic Acid Attenuates Lipid Metabolic Disorders and Liver Steatosis in DOCA-Salt Hypertensive Mice.PPAR research · 2015Article
- Nitrooleic acid protects against cisplatin nephropathy: role of COX-2/mPGES-1/PGE2 cascade.Mediators of inflammation · 2015Article
- Redox-dependent anti-inflammatory signaling actions of unsaturated fatty acids.Annual review of physiology · 2014Review
- New Insights into the PPAR γ Agonists for the Treatment of Diabetic Nephropathy.PPAR research · 2014Review
- Nitro-oleic acid protects against adriamycin-induced nephropathy in mice.American journal of physiology. Renal physiology · 2013Article
- Nitro-oleic acid is a novel anti-oxidative therapy for diabetic kidney disease.American journal of physiology. Renal physiology · 2013Article
- Combined losartan and nitro-oleic acid remarkably improves diabetic nephropathy in mice.American journal of physiology. Renal physiology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Nitroalkene derivatives of nitro-oleic acid (OA-NO(2)) are endogenous lipid products with novel signaling properties, particularly the activation of PPARs. The goal of this proposal was to examine the therapeutic potential of this OA-NO(2) in treatment of obesity and obesity-related conditions in obese Zucker rats. The animals were randomly divided to receive OA-NO(2), oleic acid (OA), both at 7.5 mug/kg/d, or vehicle ethanol via osmotic mini-pumps for 2 weeks. Following OA-NO(2) treatment, food intake was decreased as early as the first day and this effect appeared to persist throughout the experimental period. At day 14, body weight gain was significantly reduced by OA-NO(2) treatment. This treatment significantly reduced plasma triglyceride and almost normalized plasma free fatty acid and significantly increased plasma high-density lipid (HDL). The plasma TBARS and proteinuria were paralelly decreased. In contrast, none of these parameters were affected by OA treatment. After 14 days of OA-NO(2) treatment, hematocrit, a surrogate of fluid retention associated with PPARgamma agonists, remained unchanged. Together, these data demonstrated that OA-NO(2) may offer an effective and safe therapeutic intervention for obesity and obesity-related conditions.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.